The medium term support area around 309.7 CHF should allow Roche Holding AG shares to re-establish an upward trend in the short term. Investors have an opportunity to buy the stock and target the CHF 328.
The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at CHF 308.7 CHF in weekly data.
Graphically speaking, the timing seems perfect for purchasing the stock close to the CHF 309.7 support.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Within the weekly time frame the stock shows a bullish technical configuration above the support level at 308.7 CHF
The company's earnings releases usually do not meet expectations.
With an enterprise value anticipated at 4.29 times the sales for the current fiscal year, the company turns out to be overvalued.
ę MarketScreener.com 2020
Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.